At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 12 enrolled
Drug / intervention
Ketaminedrug
Likely dose
Ketamine 0.3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt
In Brief
A Phase 2 clinical trial evaluating Ketamine for Depression and Suicide. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S. Food and Drug Administration (FDA) as an anesthetic agent; however, it is not approved for use in depression treatment. The FDA allowed the use of this drug in this research study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Suicide
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartSep 2014
Primary CompletionJul 2016
Study CompletionAug 2016
TodayJul 2026
First PostedMar 24, 2014
Enrollment StartSep 1, 2014
Primary CompletionJul 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 12.3 years ago
Interventions
Ketaminedrug
0.3 mg/kg/hr of ketamine infused for 100 minutes